Extract to table
Pull the structured facts out of a document: parties, dates, amounts, obligations.
Extract to table / exhibit-d-subject-injury-indemnification.docx
exhibit-d-subject-injury-indemnification.docx
Parties
Penterra Pharmaceuticals Corp
General Counsel Penterra Pharmaceuticals Corp
Clinical Affairs Penterra Pharmaceuticals Corp
Harkness LLP
Callahan LLP
Dates
June 28, 2023
March 15, 2023
April 1, 2023
March 31, 2024
Amounts
$500,000
$15,000,000
$10,000,000
$50,000,000
$5,000,000
$20,000,000
$25,000,000
$75,000,000
Obligations
Protocol: PPC-4871-III (CLARION — Clinical Assessment of Response with Longitudinal Investigation in ONcology) Investigational Product: Penterafenib (PPC-4871) Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Agreement
In the event of any conflict between the terms of this Exhibit D and the terms of the Agreement, the terms of this Exhibit D shall govern with respect to the subject matter addressed herein, unless the Agreement expressly provides otherwise
Section 1: Definitions For purposes of this Exhibit D, the following terms shall have the meanings set forth below: 1
Additional Investigators may be added or removed during the course of the CLARION trial in accordance with the Protocol and applicable regulatory requirements, and such additions or removals shall not require an amendment to this Exhibit D
6 "Site Indemnified Parties" shall mean, collectively: (a) Veridian Health Research Network, Inc
For the avoidance of doubt, Site Indemnified Parties shall include all personnel identified on the delegation of authority log maintained at each Participating Site pursuant to the Protocol